文献速递免疫规划传染病防控与疫情报告

灭活脊髓灰质炎疫苗的鼻内与舌下黏膜接种

Intranasal and sublingual delivery of inactivated polio vaccine.
PubMed 文献 · Vaccine · 2017-04-08

本研究在小鼠中评价基于Sabin减毒株的三价灭活脊髓灰质炎疫苗(sIPV)经鼻内或舌下黏膜途径接种的可行性,并与肌内注射比较。鼻内和舌下sIPV均诱导功能性血清IgG;鼻内加佐剂组诱导的3型脊髓灰质炎病毒中和抗体滴度显著高于肌内组;黏膜接种还诱导唾液、粪便提取物和肠道组织IgA及脾脏IgA分泌B细胞,而肌内接种不能。舌下接种可能需要黏膜佐剂。

要点

  • 鼻内和舌下sIPV均诱导小鼠功能性血清IgG。
  • 鼻内sIPV加佐剂组3型中和抗体滴度显著高于肌内组。
  • 黏膜sIPV诱导唾液、粪便和肠道IgA及脾脏IgA分泌B细胞,肌内接种不能。

核心结论

  • 鼻内和舌下途径可能是完全停用OPV后及消灭脊灰后时期常规接种或疫情控制的可用方法。

研究设计与样本

  • 小鼠实验:小鼠接受三次三价sIPV免疫,途径为肌内注射、鼻内或舌下。
  • 研究还通过测试sIPV与黏膜佐剂霍乱毒素联用,评估黏膜途径是否需要佐剂。

主要发现

  • 鼻内和舌下sIPV免疫均诱导小鼠产生功能性血清IgG,经脊髓灰质炎病毒中和试验测定。
  • 鼻内给予sIPV加佐剂诱导的全身3型脊髓灰质炎病毒中和抗体滴度显著高于肌内途径给予sIPV。
  • 黏膜sIPV接种在唾液、粪便提取物和肠道组织诱导脊灰特异性IgA滴度,并在脾脏诱导产IgA的B细胞,而常规肌内接种不能做到。
  • 舌下接种很可能需要黏膜佐剂。

临床怎么用

  • 作者认为鼻内和舌下途径可能是完全停用OPV后及消灭脊灰后时期常规接种或疫情控制的可用方法。
  • 作者指出舌下黏膜途径接种的进一步研究应包括寻找安全有效的佐剂,以及开发改善口服黏膜抗原摄取的新型口服剂型,从而提高疫苗免疫原性。

局限性

  • 研究为小鼠实验,原文未报告人类数据。
  • 舌下接种很可能需要黏膜佐剂。
  • 需进一步研究舌下黏膜途径的安全有效佐剂及改善口服黏膜抗原摄取的新型口服剂型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polio is on the brink of eradication. Improved inactivated polio vaccines (IPV) are needed towards complete eradication and for the use in the period thereafter. Vaccination via mucosal surfaces has important potential advantages over intramuscular injection using conventional needle and syringe, the currently used delivery method for IPV. One of them is the ability to induce both serum and mucosal immune responses: the latter may provide protection at the port of virus entry. The current study evaluated the possibilities of polio vaccination via mucosal surfaces using IPV based on attenuated Sabin strains. Mice received three immunizations with trivalent sIPV via intramuscular injection, or via the intranasal or sublingual route. The need of an adjuvant for the mucosal routes was investigated as well, by testing sIPV in combination with the mucosal adjuvant cholera toxin. Both intranasal and sublingual sIPV immunization induced systemic polio-specific serum IgG in mice that were functional as measured by poliovirus neutralization. Intranasal administration of sIPV plus adjuvant induced significant higher systemic poliovirus type 3 neutralizing antibody titers than sIPV delivered via the intramuscular route. Moreover, mucosal sIPV delivery elicited polio-specific IgA titers at different mucosal sites (IgA in saliva, fecal extracts and intestinal tissue) and IgA-producing B-cells in the spleen, where conventional intramuscular vaccination was unable to do so. However, it is likely that a mucosal adjuvant is required for sublingual vaccination. Further research on polio vaccination via sublingual mucosal route should include the search for safe and effective adjuvants, and the development of novel oral dosage forms that improve antigen uptake by oral mucosa, thereby increasing vaccine immunogenicity. This study indicates that both the intranasal and sublingual routes might be valuable approaches for use in routine vaccination or outbreak control in the period after complete OPV cessation and post-polio eradication.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kraan H, Soema P, Amorij JP, et al. Intranasal and sublingual delivery of inactivated polio vaccine. Vaccine. 2017. PMID: 28400164. doi:10.1016/j.vaccine.2017.03.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。